The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The chair of the CDC’s newly remade vaccine advisory committee said Wednesday that the committee will be reviewing existing vaccine recommendations and assessing whether people receive too ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to high-risk adults as young as 50, too. But the CDC lacks a director to decide ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and 59 ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer influenza vaccines containing thimerosal, a mercury-based preservative ...